Taiwan Taiwan’s investment culture remains heavily oriented toward semiconductors and electronics, and few investors are yet convinced to commit capital to biotech Dr. Lin, Founder and Chief Scientific Officer of Tripartite Therapeutics, discusses the inspiration behind the company’s ADC platform of OmniLink® and Polarpeutic® technologies, designed to overcome key limitations in…
Taiwan A genuinely healthy lifestyle can help prevent neurodegenerative disease Charles S.Y. Yang discusses how his background in physics and quantum sensing led to the founding of MagQu, pioneering ultra-sensitive blood biomarker diagnostics for Alzheimer’s and other neurodegenerative diseases. He explains the company’s SQUID-based technology, commercial journey, regulatory ambitions and funding…
Taiwan Lian-Yu Chen, Director General of Taiwan’s National Health Insurance Administration, combines expertise in clinical psychiatry, public health, and governmental leadership. A PhD graduate of Johns Hopkins Bloomberg School of Public Health, she specialised in service utilisation and barriers to care. Dr Chen has driven Taiwan’s digital infrastructure and data governance…
China Founded in 2016, Mabgeek Biotech has quickly emerged as a promising innovator in immunology, pioneering long-acting antibody therapies for allergic and autoimmune diseases, particularly Th2-driven conditions such as atopic dermatitis and asthma. In this interview, Founder and CEO Dr Chenghai Zhang shares how a lean, discovery-driven model and a focus…
USA Neurvati Neurosciences is carving a distinctive path in one of medicine’s most high-risk arenas: neuroscience. In this interview, President and CEO Dr Bruce Leuchter explains how a private equity-inspired model, backed by Blackstone Life Sciences, is enabling the company to advance late-stage assets, forge global partnerships, and build a values-driven…
Switzerland Alentis Therapeutics, under the leadership of its CEO Roberto Iacone, has made significant strides in advancing innovative therapies targeting Claudin-1, a protein critical in inflammation and cancer. The company’s pipeline includes promising antibody-drug conjugates (ADCs), such as ALE.P02, currently in a Phase I/II clinical trial, and ALE.P03, expected to enter…
China EpimAb Biotherapeutics’ Chengbin Wu explains why the expansion of bispecifics into solid tumors and autoimmune diseases marks a major therapeutic turning point. He outlines how, through rational antibody engineering and unique molecule formats, EpimAb has differentiated itself with safer, more effective therapies than its competitors, as well as how the…
Puerto Rico Lucy Crespo, CEO of the Puerto Rico Science Technology and Research Trust, highlights significant recent advancements in establishing Puerto Rico as a global innovation hub, including the recent designation of Puerto Rico as one of the US Economic Development Administration’s technology hubs (Tech Hubs) and the opening of the island’s…
China Dr George Chen explores D3 Bio’s strategic approach to drug development, its ambition to launch two cancer therapies in the US within five years, and the critical role of partnerships and funding in achieving these goals. Reflecting on this journey, Dr. Chen emphasizes, “It’s a journey to realize a dream…
Portugal Health Cluster Portugal is currently spearheading a EUR 90 million EU post-COVID Recovery and Resilience Plan (RRP) project in Portugal focused on smart health, secondary use of data, and clinical trials. Executive Director Joaquim Cunha highlights the ways in which COVID acted as a catalyst for healthcare transformation more broadly,…
Hong Kong Hong Kong Exchanges and Clearing Limited (HKEX) chief executive Nicolas Aguzin has stepped down after a term fraught with upheaval. Having survived COVID-19 isolation, under Aguzin HKEX was confronted with strict regulatory crackdowns and has seen a drop in funds raised from initial public offerings by almost 40 percent. Newly…
Hong Kong Having consolidated its position as Asia’s largest biotech fundraising hub – and the world’s second largest – the Hong Kong Stock Exchange (HKEX) listed a total of 34 biotech and healthcare companies in 2021. “[Last year’s listings] made us rank first by number of deals and second by the amount…
See our Cookie Privacy Policy Here
